Last reviewed · How we verify

NCT05667337: CLP-PEG-MPC

Open-label Prospective Clinical Trial Evaluating the Safety and Efficacy of Biosynthetic CLP-PEG-MPC Corneal Implants in Patients Undergoing High-risk Deep Anterior Lamellar Keratoplasty.

Withdrawn NA Last updated 28 December 2022
What this trial tests

NA trial testing CLP-PEG-MPC in High-risk Corneal Transplantation. Withdrawn.

Timeline
1 January 2026
Primary endpoint
1 January 2040
1 June 2040

Quick facts

Lead sponsorCentre hospitalier de l'Université de Montréal (CHUM)
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Start date1 January 2026
Primary completion1 January 2040
Estimated completion1 June 2040

Drugs / interventions tested

Conditions studied

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Adults 18 to 99, any sex, with High-risk Corneal Transplantation or Corneal Blindess. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label and prospective clinical trial, in which a maximum of 5 eyes of 5 patients will receive a CLP-PEG-MPC synthetic cornea during deep anterior lamellar keratoplasty (DALK) surgery and will be followed up over 24 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing